For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue from collaborative arrangement | 0 | 0 | 0 | 0 |
| Research and development | 14,070,107 | 10,261,236 | 13,333,329 | 14,521,407 |
| General and administrative | 7,879,886 | 7,215,365 | 7,877,126 | 8,563,112 |
| Total operating expenses | 21,949,993 | 17,476,601 | 21,210,455 | 23,084,519 |
| Loss from operations | -21,949,993 | -17,476,601 | -21,210,455 | -23,084,519 |
| Interest income | 439,593 | 449,337* | 552,108 | 610,638 |
| Interest expense | - | 0* | 0 | 0 |
| Change in fair value of common stock warrant liabilities | -4,137,703 | -21,174,099 | 22,515,730 | 1,878,010 |
| (gain) loss on investment in affiliated entity | -2,103,688 | -392,042 | -589,618 | 776,373 |
| Net unrealized gain on available-for-sale equity securities | 79,077 | 9,999 | 205,259 | 759,289 |
| Other expense, net | -285,490 | 88 | -1,938,236 | -703,183 |
| Net gain | -19,682,798 | 3,764,880 | -45,496,672 | -23,519,412 |
| Basic EPS | -0.28 | 0.065 | -0.87 | -0.61 |
| Diluted EPS | -0.28 | 0.065 | -0.87 | -0.61 |
| Basic Average Shares | 69,101,910 | 57,933,252 | 52,168,694 | 38,830,053 |
| Diluted Average Shares | 69,101,910 | 57,933,252 | 52,168,694 | 38,830,053 |
INOVIO PHARMACEUTICALS, INC. (INO)
INOVIO PHARMACEUTICALS, INC. (INO)